Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study

Klara Rosta, Johannes Ott, Fanni Kelemen, Wilhelm Temsch, Tobias Lahner, Theresa Reischer, Hanns Helmer, Aniko Somogyi

Research output: Article

4 Citations (Scopus)


Purpose: To determine the incidence of gestational diabetes mellitus (GDM) in pregnant women who received vaginal progesterone due to short cervical length or to prevent recurrent preterm birth. Methods: In this retrospective study, we included 190 women with singleton pregnancies at risk for preterm birth who received vaginal natural progesterone (200 mg daily between gestational weeks 16 + 0 and 36 + 0) for a minimum of 4 weeks and delivered > 28 weeks. The control group consisted of 242 age- and body mass index (BMI)-matched patients without progesterone administration. Data were acquired from a database containing prospectively collected information. Patients with pre-existing diabetes, and conception after in vitro fertilisation procedure were excluded. Results: The incidence of GDM did not differ significantly between the progesterone-treated and the control group (14.7% vs. 16.9%, respectively; p = 0.597). In a binary regression model, patients with higher pre-pregnancy BMI (OR 1.1; p = 0.006), and those with a family history of diabetes had a higher risk for GDM development (OR 1.8; p = 0.040), whereas vaginal progesterone treatment had no significant influence (p = 0.580). Conclusion: The use of vaginal progesterone for the prevention of recurrent preterm delivery and in women with a short cervix does not seem to be associated with an increased risk of GDM.

Original languageEnglish
Pages (from-to)1079-1084
Number of pages6
JournalArchives of Gynecology and Obstetrics
Issue number6
Publication statusPublished - dec. 1 2018


ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this